Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis.

Shah HH, Patel C.

Ren Fail. 2013 Sep;35(8):1182-5. doi: 10.3109/0886022X.2013.815568. Epub 2013 Jul 23.

PMID:
23879705
2.
3.

Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.

Alsaran K, Sabry A, Molhem A.

Ren Fail. 2013;35(10):1305-9. doi: 10.3109/0886022X.2013.826136. Epub 2013 Sep 24.

PMID:
24059964
5.
6.

Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.

Donato MF, Fabrizi F, Fogazzi GB, Cresseri D, Passerini P, Martin P, Messa P.

Int J Artif Organs. 2013 Jan;36(1):63-8. doi: 10.5301/ijao.5000166. Review.

PMID:
23280083
7.

[Focal segmental glomerulosclerosis associated with type C virus hepatitis and decrement of proteinuria by interferon-alpha therapy].

Ezaki Y, Tanaka U, Minoshima S, Endou M, Kuwaki K, Arimura Y, Nakabayashi K, Nagasawa T.

Nihon Jinzo Gakkai Shi. 1999 Apr;41(2):83-8. Japanese.

PMID:
10361424
8.

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

Alsaran K, Sabry A, Shaheen N.

Int Urol Nephrol. 2011 Sep;43(3):865-73. doi: 10.1007/s11255-010-9756-1. Epub 2010 May 19.

PMID:
20490669
9.

Focal segmental glomerulosclerosis and hepatitis C virus: a case report.

Motta M, Malaguarnera M, Restuccia N, Romano M, Vinci E, Pistone G.

Panminerva Med. 2001 Mar;43(1):49-52.

PMID:
11319519
10.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

11.

Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.

Sood A, Midha V, Sandhu JS, Sood N, Kaur A, Mittal R, Puri S.

Indian J Gastroenterol. 2010 Jun;29(3):124-5. No abstract available.

PMID:
20803821
12.

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W.

Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Epub 2014 Dec 5. Erratum in: Lancet Infect Dis. 2016 Apr;16(4):404.

PMID:
25482330
13.

Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.

García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C.

World J Gastroenterol. 2013 Mar 28;19(12):1943-52. doi: 10.3748/wjg.v19.i12.1943.

14.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

15.

Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.

Alves Couto C, Costa Faria L, Dias Ribeiro D, de Paula Farah K, de Melo Couto OF, de Abreu Ferrari TC.

Liver Int. 2006 Dec;26(10):1294-7.

PMID:
17105597
16.
17.

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P.

Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.

PMID:
24119723
18.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

19.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):403-13. doi: 10.1016/S0140-6736(14)60494-3. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907225
20.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Hartwell D, Cooper K, Frampton GK, Baxter L, Loveman E.

Health Technol Assess. 2014 Oct;18(65):i-xxii, 1-202. doi: 10.3310/hta18650. Review.

Supplemental Content

Support Center